Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Form 8.3 -INSTEM PLC

3 Oct 2023 14:25

RNS Number : 5625O
Barclays PLC
03 October 2023
 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR

MORE

Rule 8.3 of the Takeover Code (the "Code")

1.

KEY INFORMATION

(a)

Full name of discloser:

 

Barclays PLC.

(b)

Owner or controller of interest and short

 

 

positions disclosed, if different from 1(a):

(c)

Name of offeror/offeree in relation to whose

INSTEM PLC

 

relevant securities this form relates:

(d)

If an exempt fund manager connected with an

 

 

offeror/offeree, state this and specify identity of

 

offeror/offeree:

(e)

Date position held/dealing undertaken:

02 Oct 2023

(f)

In addition to the company in 1(c) above, is the discloser making

NO

 

 

 

disclosures in respect of any other party to the offer?

 

 

2.

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)

Interests and short positions in the relevant securities of the offeror or offeree

 

 

to which the disclosure relates following the dealing(if any)

 

Class of relevant security:

10p ordinary

 

Interests

Short Positions

 

Number

(%)

Number

(%)

(1)

Relevant securities owned

 

 

 

 

 

and/or controlled:

 

 

325,000

1.42%

0

0.00%

(2)

Cash-settled derivatives:

 

 

 

 

 

and/or controlled:

 

 

0

0.00%

325,000

1.42%

(3)

Stock-settled derivatives (including options)

 

 

 

 

 

and agreements to purchase/sell:

 

 

0

0.00%

0

0.00%

 

 

 

 

 

 

 

 

 

TOTAL:

 

 

325,000

1.42%

325,000

1.42%

(b)

Rights to subscribe for new securities (including directors and other executive

 

 

options)

 

 

 

 

 

 

Class of relevant security in relation to

 

 

 

 

which subscription right exists

 

 

 

 

Details, including nature of the rights

 

 

 

 

concerned and relevant percentages:

 

 

 

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

 

 

 

 

 

Class of relevant

Purchase/sale

Number of

Price per unit

security

 

securities

 

10p ordinary

Purchase

32,393

8.2057Ă‚ GBP

10p ordinary

Purchase

17,607

8.2549Ă‚ GBP

 

 

 

 

 

 

 

 

(b)

Cash-settled derivative transactions

 

Class of

Product

Nature of dealing

Number of

Price per

relevant

description

 

reference

unit

security

 

 

securities

 

10p ordinary

SWAP

Short

17,607

8.2549Ă‚ GBP

10p ordinary

SWAP

Short

32,393

8.2057Ă‚ GBP

 

 

 

 

 

 

 

 

(c)

Stock-settled derivative transactions (including options)

 

(i)

Writing, selling, purchasing or varying

 

Class

Product

Writing,

Number

Exercise

Type

Expiry

Option

of

description

purchasing,

of

price

 

date

money

relevant

 

selling,

securities

per unit

 

 

paid/

security

 

varying etc

to which

 

 

 

received

 

 

 

option

 

 

 

per unit

 

 

 

relates

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(ii)

Exercising

 

 

 

 

 

 

Class of relevant

Product description

Exercising/ exercised against

Number of

Exercise price per

security

 

 

securities

unit

 

 

 

 

 

 

 

 

 

 

 

 

 

(d)

Other dealings (including subscribing for new securities)

 

Class of relevant

Nature of Dealings

Details

Price per unit (if

security

 

 

applicable)

 

 

 

 

4.

OTHER INFORMATION

(a)

Indemnity and other dealings arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding,

 

 

formal or informal, relating to relevant securities which may be an inducement to deal

 

 

or refrain from dealing entered into by the exempt principal trader making the disclosure and any party

 

to the offer or any person acting in concert with a party to the offer:

 

 

 

NONE

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between

 

 

the person making the disclosure and any other person relating to:

 

 

(i)Ă‚ the voting rights of any relevant securities under any option; or

 

 

 

(ii) the voting rights of future acquisition or disposal of any relevant securities to which

 

 

any derivative is referenced:

 

 

 

 

 

 

NONE

(c)

Attachments

 

 

 

 

 

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

03 Oct 2023

Contact name:

Large Holdings Regulatory Operations

Telephone number:

020 3134 7213

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETNKNBBNBDDQKK
Date   Source Headline
25th Feb 201610:17 amRNSHolding(s) in Company
23rd Feb 20161:32 pmRNSResult of General Meeting and Director Dealings
12th Feb 20167:00 amRNSInvestor Presentation
5th Feb 20164:47 pmRNSIssue of Equity and Total Voting Rights
4th Feb 20167:00 amRNSDirector/PDMR Shareholding
3rd Feb 20167:00 amRNSPlacing, Posting of Circular and Notice of GM
25th Jan 20167:00 amRNSInnovators & Investors Forum
13th Jan 20167:00 amRNSTrading Update
23rd Dec 20151:15 pmRNSDirector Shareholding and Other Holdings
8th Dec 20153:53 pmRNSIssue of Equity and Total Voting Rights
1st Dec 20157:00 amRNSLogos Earn Out, Issue of Equity and TVR
30th Nov 20155:59 pmRNSHolding(s) in Company
29th Sep 20157:00 amRNSHalf Yearly Report
6th Aug 201511:55 amRNSAdmission of Ordinary Shares
3rd Aug 20157:00 amRNSLogos Third Earn Out Payment & Total Voting Rights
30th Jul 20157:00 amRNSTrading Update and Notice of Interim Results
29th Jul 20157:01 amRNSGrants Under the Long Term Incentive Plan
23rd Jun 20157:00 amRNSInvestor Teach-in
21st May 20154:39 pmRNSHolding(s) in Company
19th May 20151:16 pmRNSResult of AGM
14th May 20157:00 amRNSInstem ALPHADAS Contract Wins
27th Apr 20159:16 amRNSPosting of Annual Report and Notice of AGM
30th Mar 20157:00 amRNSFinal Results
16th Mar 20157:00 amRNSNotice of Results
13th Feb 20157:00 amRNSPerceptive Instruments Earn Out Payment
27th Jan 20157:01 amRNSInnovators & Investors Forum (London)
12th Jan 20157:00 amRNSTrading Update and Notice of Results
23rd Dec 201411:52 amRNSHolding(s) in Company
18th Dec 20147:00 amRNSWIL Research Contract Extension
10th Nov 20147:00 amRNSCentrus-submit Contract Wins
24th Sep 20147:00 amRNSUnaudited Interim Results
5th Sep 20147:00 amRNSNotice of Results
13th Aug 201410:27 amRNSHolding(s) in Company
1st Aug 20147:00 amRNSLogos Second Earn Out Payment
16th Jul 20147:00 amRNSTwo contract wins in Asia-Pacific
21st May 201411:45 amRNSResult of AGM
1st May 20147:00 amRNSContract win
25th Apr 20147:00 amRNSPosting of Annual Report and Notice of AGM
26th Mar 20147:01 amRNSUS Government Contract Extension
26th Mar 20147:00 amRNSFinal Results
6th Mar 20147:00 amRNSNotice of Results
20th Feb 20147:00 amRNSThree-Year SaaS Contract with Leading Pharma
7th Feb 20141:05 pmRNSHolding(s) in Company
3rd Feb 20147:00 amRNSLogos Initial Earn Out Payment
8th Jan 20147:00 amRNSTrading Update and Notice of Results
22nd Nov 20137:00 amRNSAcquisition and Trading Update
9th Oct 20137:00 amRNSAppointment of VP Global Sales
25th Sep 20137:00 amRNSHalf Yearly Report
15th Aug 20137:00 amRNSNotice of Results
2nd Jul 20137:00 amRNSFirst Contract Win for Instem Clinical

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.